Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say

Core Insights - Astrazeneca reported $13.59 billion in revenue for Q1 2025, a year-over-year increase of 7.2% [1] - The EPS for the same period was $1.24, compared to $1.03 a year ago, representing a surprise of +12.73% over the consensus estimate [1][3] - The revenue fell short of the Zacks Consensus Estimate by -0.66% [1] Financial Performance - Astrazeneca's stock has returned -4.9% over the past month, underperforming the Zacks S&P 500 composite's -0.8% change [3] - The company currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3] Key Product Metrics - Oncology product Tagrisso generated $678 million in the U.S., slightly below the average estimate of $684.78 million [4] - BioPharmaceuticals product Farxiga in Established RoW reported $120 million, exceeding the estimate of $101.67 million, with a year-over-year change of +11.1% [4] - Oncology product Enhertu in Established RoW achieved $19 million, compared to the estimate of $21.59 million, reflecting a year-over-year increase of +46.2% [4] - Enhertu in Europe reported $43 million, surpassing the estimate of $36.98 million, with a year-over-year change of +65.4% [4] - BioPharmaceuticals product Symbicort generated $723 million, below the estimate of $772.02 million [4] - Pulmicort reported $158 million, compared to the estimate of $197.96 million [4] - Crestor achieved $316 million, exceeding the estimate of $294.03 million, with a year-over-year change of +6.4% [4] - Seloken/Toprol-XL reported $161 million, slightly above the estimate of $154.45 million, with a year-over-year change of -2.4% [4] - Tagrisso worldwide generated $1.68 billion, slightly above the estimate of $1.67 billion, reflecting a year-over-year change of +5.3% [4] - Synagis reported $112 million, below the estimate of $132.88 million, with a year-over-year change of -34.5% [4] - Fasenra achieved $418 million, exceeding the estimate of $379.51 million [4] - Brilinta reported $305 million, above the estimate of $263.03 million, with a year-over-year change of -5.6% [4]